ALSO IN THIS MONTH'S ISSUE

  • Companies To Watch: CinCor Pharma

    CinCor Pharma is uncovering a great potential for combatting treatment-resistant and uncontrolled hypertension.

  • What Does The Future Hold For China’s Biopharma Industry?

    Chinese biopharma stock prices have been on a roller coaster ride, with some composites reaching historical highs in June 2021 but heading south ever since. In this article, we deep dive into what enabled this sudden rise and examine whether the future of China’s biopharma industry looks as bleak as the stock market suggests.

  • CoCrystal’s Co-CEOs

    Most biopharma industry observers would agree the leadership of a company by two co-equal CEOs is a rare thing. But when it does happen, the unusual arrangement offers useful insights.

  • 3 Approaches For Developing Better Drugs To Treat Brain Disorders

    Three organizations pursuing three different strategies for new drug development have one thing in common: optimism about the future of treatments for intractable brain disorders.

BEYOND THE PRINTED PAGE

  • MAPS: Walking The Talk On Intellectual Property?
    4/29/2022

    Did MAPS, a leader in the psychedelic medicines space, just make good on its promise to share its intellectual property, as opposed to wielding it against competitors?

  • Where Patients Meet Policy: The EveryLife Foundation For Rare Diseases
    4/1/2022

    The year before he founded Ultragenyx, Emil Kakkis created the EveryLife Foundation for Rare Diseases, a nonprofit patient advocacy organization focused on the “equitable development of and access to lifesaving diagnoses, treatments, and cures.” We caught up with Annie Kennedy, chief of policy and advocacy at the EveryLife Foundation, to learn more about the issues and policies the foundation is prioritizing this year.

  • Ever Learn A Lesson The Hard Way?
    1/24/2022

    Bernard Coulie, M.D., Ph.D., president and CEO of Pliant Therapeutics, a company developing treatments for fibrotic diseases, shares a lesson learned the hard way involving an exit from a previous startup.

JUNE 2022 DIGITAL EDITION

2022 CMO & CRO AWARDS EDITION

@LIFESCILEADER1